|Ask||100.00 x 200|
|Day's Range||84.95 - 89.90|
|52 Week Range||28.14 - 92.00|
|PE Ratio (TTM)||-11.00|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck.
How Alnylam, Puma, Immunogen, Sangamo, and Calithera beat all others to be the best biotech stocks of the year so far.
Puma's stock has significantly outperformed the Zacks classified Medical-Biomed/Genetics industry in the year so far after an FDA advisory committee recommended approval for neratinib in May this year.